NCT03662971View on ClinicalTrials.gov

Evaluate the Tolerance, Safety and Pharmacokinetics of Germinal Peptide Eye Drops in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

October 29, 2018

Primary Completion Date

December 4, 2018

Study Completion Date

October 24, 2019

Conditions
Corneal Defect
Interventions
DRUG

Germinal peptide eye drops

Germinal peptide eye drops of 0.0005%, 0.001%, 0.002%, 0.004% and 0.008%

Trial Locations (1)

BJ10

Xiuli Zhao, Beijing

All Listed Sponsors
lead

Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd.

INDUSTRY

NCT03662971 - Evaluate the Tolerance, Safety and Pharmacokinetics of Germinal Peptide Eye Drops in Healthy Volunteers | Biotech Hunter | Biotech Hunter